share_log

欧林生物(688319.SH):三价流感病毒裂解疫苗(MDCK细胞)获得药物临床试验批准通知书

Olin Biology (688319.SH): Trivalent influenza virus split lytic vaccine (MDCK cells) has obtained the drug clinical trial approval notification.

Gelonghui Finance ·  Oct 21, 2024 16:52

On October 21st, Olin Biomedical (688319.SH) announced that it has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the trivalent influenza virus split vaccine (MDCK cells), which can stimulate the body to produce immunity against influenza viruses after vaccination, used to prevent epidemic influenza caused by vaccine-related types of influenza viruses. Currently, in terms of vaccine components and the types of viruses being prevented, the influenza vaccines available in China include trivalent and quadrivalent influenza vaccines. The trivalent influenza vaccine mainly prevents H1N1, H3N2 subtypes of influenza A, and influenza B virus of the Victoria lineage.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment